Skip to content
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Middle East
    موقعك
  • Request information
  • 800 50342
    طلب معلومات 800 50342
  • عربي
  • 800 50342
    طلب معلومات 800 50342
  • Part of brands: |
Middle EastMiddle East
  • Part of brands: |
  • We guide you
    • Fertility
    • Inherited diseases
    • Worry-free pregnancy
  • Reproductive Health
    • Specialists
      • ERA
      • EndomeTRIO
      • EMMA
      • ALICE
      • PGT-A
      • Baby Gender
      • EMBRACE
      • PGT-M
      • PGT-SR
      • POC
      • WES
      • NACE
      • SAT
    • Patients
      • ERA
      • EndomeTRIO
      • EMMA
      • ALICE
      • PGT-A
      • Baby Gender
      • EMBRACE
      • PGT-M
      • PGT-SR
      • POC
      • WES
      • NACE
      • SAT
  • Diagnostics
  • About Us
    • Igenomix Research
    • About Igenomix
  • Our blog
  • Clinic Portal
  • ACADEMY
Genomics Precision Diagnostic > Oncology > Prostate Cancer

Prostate Cancer

Prostate cancer is the second most common cancer in men after skin cancer and the second leading cause of cancer death in men after lung cancer. Risk factors for prostate cancer include increased age, family history and black race
Overview
Indication
Clinical Utility
Genes & Diseases
Methodology
References

Overview

  • Prostate cancer is the second most common cancer in men after skin cancer and the second leading cause of cancer death in men after lung cancer. Risk factors for prostate cancer include increased age, family history and black race. In early stages, prostate cancer is asymptomatic and is typically detected by screening. Although many prostate cancers are sporadic, about 5-15% of prostate cancer diagnoses may be associated with a strong hereditary component. Genetic testing has found its place in routine testing for breast, ovarian and prostate cancers amongst others, providing actionable preventive measures to increase life expectancy and quality of life.
  • Hereditary cancer syndromes are encountered in all medical specialties. Although they account for about 5% of all malignancies, it is of special importance to identify these patients because, unlike patients with sporadic cancers, they require special, long-term care as their predisposition can cause them to develop certain tumors at a relatively early age. Most hereditary cancers are associated with a “germline mutation” that will be present in every cell of the human body. Identification of patients at risk of inherited cancer susceptibility is dependent upon the ability to characterize genes and alterations associated with increased cancer risk as well as gathering a detailed personal and family history aiding in the identification of the mode of inheritance as well as other family members at risk of suffering from this susceptibility. Most hereditary cancer syndromes follow an autosomal dominant inheritance, and the penetrance is high.
  • The Igenomix Prostate Cancer Precision Panel provides a comprehensive analysis of the most common genes responsible for the development of a malignant growth in the prostate using next-generation sequencing (NGS) to fully understand the spectrum of relevant lung cancer predisposition genes.

Indication

The Igenomix Comprehensive Inherited Caner Precision Panel is indicated as a screening and diagnostic test in those cases where there are: 

  • Family history of prostate cancer
  • Blood in the urine
  • Frequent urination  
  • Urge to urinate
  • Pain or burning during urination
  • Weak or interrupted urine flow
  • Fatique
  • Lower back pain
  • Change in bowel habits
  • Unintentional weight loss

Clinical Utility

The clinical utility of this panel is: 

  • The genetic and molecular diagnosis for an accurate clinical diagnosis of a patient with personal or family history suggestive of a hereditary cancer syndrome with predisposition to prostate cancer.
  • Early initation of treatment with a multidisciplinary team for appropriate total body screening, early surgical intervention, or pharmacologic treatment. 
  • Risk assessment and genetic counselling of asymptomatic family members according to the mode of inheritance. 
  • Reduce morbidity related toprostate cancer, or morbidity secondary to complications of surveillance and treatment.
  • Categorization of genetic alterations into predictive levels of standard, investigational or hypothetic target therapies in the molecular pathology reports.
  • Improved pathways from diagnosis to treatment in susceptible populations.

Genes & Diseases

Methodology

References

See scientific referrals

National Comprehensive Cancer Network.  (2021). Retrievedfrom https://www.nccn.org/professionals/physician_gls/default.aspx#detection

Zhen, J. T., Syed, J., Nguyen, K. A., Leapman, M. S., Agarwal, N., Brierley, K., Llor, X., Hofstatter, E., &Shuch, B. (2018). Genetic testing for hereditary prostate cancer: Current status and limitations. Cancer, 124(15), 3105–3117. https://doi.org/10.1002/cncr.31316

Heidegger, I., Tsaur, I., Borgmann, H., Surcel, C., Kretschmer, A., Mathieu, R., Visschere, P., Valerio, M., van den Bergh, R., Ost, P., Tilki, D., Gandaglia, G., Ploussard, G., & EAU-YAU Prostate Cancer Working Party (2019). Hereditary prostate cancer – Primetime for genetic testing?. Cancer treatment reviews, 81, 101927. https://doi.org/10.1016/j.ctrv.2019.101927

Pilarski R. (2019). The Role of BRCATesting in Hereditary Pancreatic and Prostate Cancer Families. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 39, 79–86. https://doi.org/10.1200/EDBK_238977

Tan, S. H., Petrovics, G., &Srivastava, S. (2018). Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities. International journal of molecular sciences, 19(4), 1255. https://doi.org/10.3390/ijms19041255

Heise, M., & Haus, O. (2014). Dziedzicznyrakgruczołukrokowego [Hereditary prostate cancer]. Postepyhigieny i medycynydoswiadczalnej (Online), 68, 653–665. https://doi.org/10.5604/17322693.1104682

Pritzlaff, M., Tian, Y., Reineke, P., Stuenkel, A. J., Allen, K., Gutierrez, S., Jackson, M., Dolinsky, J. S., LaDuca, H., Xu, J., Black, M. H., & Helfand, B. T. (2020). Diagnosing hereditary cancer predisposition in men with prostate cancer. Genetics in medicine : official journal of the American College of Medical Genetics, 22(9), 1517–1523. https://doi.org/10.1038/s41436-020-0830-5

 

descargar

Detail description

Download

 

IGENOMIX_PartOfVitrolifeGroup_black

WE GUIDE YOU

Fertility

Inherited diseases prevention

Healthy pregnancy

 

CAP Accredited laboratory delivering optimal patient care & evolving with innovation in laboratory medicine.

 

OUR SERVICES

Genetic solutions

For Patients

How to send a sample?

Igenomix Dubai is accredited by EIAC (Emirates international accreditation center) to the ISO 15189 standard for Whole exome sequencing (See scope of accreditation in certificate)

ABOUT US

About Igenomix

Contact

Quality

Work with us

FOLLOW IGENOMIX

Blog: Path to fertility

  800 50342
  Write us
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
Language

[2024] © Igenomix Privacy policy Quality policy Legal note Cookies policy

Request information

  • We guide you
    • Fertility
    • Inherited diseases
    • Worry-free pregnancy
  • Reproductive Health
    • Specialists
      • ERA
      • EndomeTRIO
      • EMMA
      • ALICE
      • PGT-A
      • Baby Gender
      • EMBRACE
      • PGT-M
      • PGT-SR
      • POC
      • WES
      • NACE
      • SAT
    • Patients
      • ERA
      • EndomeTRIO
      • EMMA
      • ALICE
      • PGT-A
      • Baby Gender
      • EMBRACE
      • PGT-M
      • PGT-SR
      • POC
      • WES
      • NACE
      • SAT
  • Diagnostics
  • About Us
    • Igenomix Research
    • About Igenomix
  • Our blog
  • Clinic Portal
  • ACADEMY
  • Middle East
    موقعك
  • Languages
    • You need Polylang or WPML plugin for this to work. You can remove it from Theme Options.
  • Request information
We use our own and third-party cookies to improve our services and to show you advertisements related to your preferences by analyzing your browsing habits. If you continue browsing, it is considered that you accept its use.Cookie settingsAccept
Privacy & Cookies Policy

نظرة عامة على الخصوصية

يستخدم هذا الموقع ملفات تعريف الارتباط لتحسين تجربتك أثناء التنقل عبر الموقع. من بين ملفات تعريف الارتباط هذه ، يتم تخزين ملفات تعريف الارتباط المصنفة حسب الضرورة على متصفحك لأنها ضرورية لعمل الوظائف الأساسية للموقع. نستخدم أيضًا ملفات تعريف الارتباط الخاصة بطرف ثالث والتي تساعدنا في تحليل وفهم كيفية استخدامك لهذا الموقع. سيتم تخزين ملفات تعريف الارتباط هذه في متصفحك فقط بموافقتك. لديك أيضًا خيار إلغاء الاشتراك في ملفات تعريف الارتباط هذه. لكن إلغاء الاشتراك في بعض ملفات تعريف الارتباط هذه قد يكون له تأثير على تجربة التصفح لديك.
Necessary
Always Enabled
أي ملفات تعريف ارتباط قد لا تكون ضرورية بشكل خاص لكي يعمل موقع الويب ويتم استخدامها خصيصًا لجمع بيانات المستخدم الشخصية عبر التحليلات والإعلانات والمحتويات الأخرى المضمنة تسمى ملفات تعريف ارتباط غير ضرورية. من الضروري الحصول على موافقة المستخدم قبل تشغيل ملفات تعريف الارتباط هذه على موقع الويب الخاص بك.
Non-necessary
أي ملفات تعريف ارتباط قد لا تكون ضرورية بشكل خاص لكي يعمل موقع الويب ويتم استخدامها خصيصًا لجمع بيانات المستخدم الشخصية عبر التحليلات والإعلانات والمحتويات الأخرى المضمنة تسمى ملفات تعريف ارتباط غير ضرورية. من الضروري الحصول على موافقة المستخدم قبل تشغيل ملفات تعريف الارتباط هذه على موقع الويب الخاص بك.
SAVE & ACCEPT